Results 21 to 30 of about 8,600 (158)

Malignant Myeloma in a Patient after Treatment for Osteoporosis with Teriparatide; a Rare Coincidence

Clinical Medicine Insights: Case Reports, 2008
A breakthrough in understanding of mechanisms of bone structure regulation has brought about the introduction of the new synthetic recombinant human parathyroid hormone 1–34 (PTH1-34; Teriparatide) in the treatment of osteoporosis.
Terje Forslund, Anna-Mari Koski, Arvo Koistinen, Anu Sikiö   +3 more
doaj   +1 more source

Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment

BMC Musculoskeletal Disorders, 2017
Background Atypical subtrochanteric fracture and femoral fracture have been considered to be rare complications related to long-term bisphosphonates use. A reduced bone turnover rate may lead to delayed bone healing.
Wen-Ling Yeh, Chun-Yi Su, Chia-Wei Chang, Chien-Hao Chen, Tsai-Sheng Fu, Lih-Huei Chen, Tung-Yi Lin   +6 more
doaj   +1 more source

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment

Bone Reports, 2020
Introduction: Osteoporosis is one of the serious adverse effects associated with glucocorticoid therapy. Although bisphosphonates have been used for glucocorticoid-induced osteoporosis (GIO), some patients have shown an inadequate response. In such cases,
Yasuaki Hirooka, Yuji Nozaki, Asuka Inoue, Jinhai Li, Toshihiko Shiga, Kazuya Kishimoto, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +9 more
doaj   +1 more source

Does Early Treatment With Teriparatide Prevent the Need for Surgical Intervention in Osteoporotic Vertebral Compression Fractures

Global Spine Journal
Study Design Retrospective Cohort Study. Objective The primary objective of this study is to evaluate the efficacy of early administration of Teriparatide in preventing the necessity of surgical intervention in individuals with osteoporotic vertebral ...
Vishnu Vikraman Nair MBBS, MS, Vishal Kundnani MS   +1 more
doaj   +1 more source

Evaluation of Teriparatide for Treatment of Osteoporosis in Four Patients with Cystic Fibrosis: A Case Series

Case Reports in Endocrinology, 2014
Introduction. Bone disease is a common complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of teriparatide, recombinant human parathyroid hormone, to treat CF-related bone disease. Case Presentation.
Oranan Siwamogsatham, Kelly Stephens, Vin Tangpricha   +2 more
doaj   +1 more source

Pregnancy‐ and lactation‐associated osteoporosis: A position statement of the IAPM, IOF, ECTS, ESCEO, IMS, and EMAS

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Pregnancy‐ and lactation‐associated osteoporosis (PLO) is a syndrome characterized by fragility fractures (most commonly vertebral, often multiple) occurring in late pregnancy or the early postpartum period. This position statement summarizes the current knowledge of PLO, and the recommended procedure for assessment, diagnosis and treatment ...
Peyman Hadji, Apostolos Athanasiadis, Maria‐Luisa Brandi, Marlene Chakhtoura, Manju Chandran, Frank Chervenak, Amos Grünebaum, Irene Lambrinoudaki, Willem F. Lems, Apostolos M. Mamopoulos, Eugene McCloskey, Rossella E. Nappi, Jessica Pepe, Jean‐Yves Reginster, René Rizzoli, Petra Stute, Şansın Tuzun, Amanda J. Vincent, Maria Belen Zanchetta, M. Carola Zillikens, Ioannis Kyvernitakis   +20 more
wiley   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor, Emily J. Henderson, Emma Tenison   +2 more
wiley   +1 more source

Type 2 Diabetes Is Associated With Increased Complications and Mortality After Hip Fracture in Older Adults Aged 60 Years or Older

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes (T2D) is associated with increased hip fracture risk. We evaluated the impact of T2D on post‐hip fracture outcomes, which is less well described. Materials and Methods Individuals aged ≥ 60 years hospitalised for hip fractures between 2011 and 2020 were identified from the territory‐wide electronic health records of Hong ...
Xincheng Zou, Manju Chandran, Xi Xiong, Chi‐Ho Lee, Wing‐Sun Chow, Carol H. Y. Fong, Lawrence C. M. Lau, Ka‐Shing Cheung, Carlos K. H. Wong, Kathryn C. B. Tan, Yu‐Cho Woo, Karen S. L. Lam, David T. W. Lui   +12 more
wiley   +1 more source

Bone health in adults with non‐ambulatory neuromuscular disorders: scoping review of risk factors, diagnosis and management

Internal Medicine Journal, EarlyView.
Abstract Background Non‐ambulatory adults have an increased risk of osteoporosis and fractures due to reduced weight‐bearing and diminished neuromuscular stimulation, resulting in substantial morbidity and mortality. Aims This scoping review aimed to systematically evaluate risk factors, diagnostic indicators and management strategies for optimising ...
Thomas Bailey, Carolyn Droste, John A. Eisman, Steven G. Faux, Arnagretta Hunter   +4 more
wiley   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source